Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Hematology

Cognitive Impairment After 6 and 12 Months of Hodgkin Lymphoma Treatment

Hematological Oncology

English

Host Genetic Variation in the TNF and Nf-ĸb Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of 2 Studies

Hematological Oncology

English

Chemotherapy or Combined Modality Therapy for Early-Stage Hodgkin Lymphoma

Hematological Oncology

English

Obinutuzumab Therapy in Patients With Marginal Zone and Mantle Cell Lymphoma

Hematological Oncology

English

Idelalisib Plus Anti-Cd20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Hematological Oncology

English

Allograft Rejection Associated With Immunosuppression Reduction for Post-Transplant Lymphoproliferative Disorder: A 20-Year Single-Institutional Experience

Hematological Oncology

English

Persistent Mediastinal Positron Emission Tomography (Pet)-Positivity After Frontline Therapy for Hodgkin Lymphoma Is Best Managed by Close Observation

Hematological Oncology

English

Prognostic Value of Immunohistochemical Markers in Stage Iii/Iv Classical Hodgkin Lymphoma Treated Frontline in the Lysa Eortc 20012 Randomized Protocol

Hematological Oncology

English

Kras and Ago2 Interaction Promote Initiation of Plasmablastic Lymphoma Using an in Vivo Mouse Transplant Model

Hematological Oncology

English

Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Hematology

Cognitive Impairment After 6 and 12 Months of Hodgkin Lymphoma Treatment

Host Genetic Variation in the TNF and Nf-ĸb Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of 2 Studies

Chemotherapy or Combined Modality Therapy for Early-Stage Hodgkin Lymphoma

Obinutuzumab Therapy in Patients With Marginal Zone and Mantle Cell Lymphoma

Idelalisib Plus Anti-Cd20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Allograft Rejection Associated With Immunosuppression Reduction for Post-Transplant Lymphoproliferative Disorder: A 20-Year Single-Institutional Experience

Persistent Mediastinal Positron Emission Tomography (Pet)-Positivity After Frontline Therapy for Hodgkin Lymphoma Is Best Managed by Close Observation

Prognostic Value of Immunohistochemical Markers in Stage Iii/Iv Classical Hodgkin Lymphoma Treated Frontline in the Lysa Eortc 20012 Randomized Protocol

Kras and Ago2 Interaction Promote Initiation of Plasmablastic Lymphoma Using an in Vivo Mouse Transplant Model

Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status